title: Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose.
abstract: BACKGROUND
  An anion exchange resin has been reported to lower blood glucose levels in patients with type 2 diabetes.
  
  
  OBJECTIVE
  To examine, in comparison with an alpha-glucosidase inhibitor, the usefulness of colestimide in lowering blood glucose levels in patients with type 2 diabetes and hypercholesterolemia.
  
  
  METHODS
  Thirty-three patients with type 2 diabetes and hypercholesterolemia were more or less randomly assigned to receive either colestimide (17 patients) or acarbose (16 patients). At 10 time points before and after administration, plasma glucose levels and serum lipid concentrations were measured in all subjects, and the J-index and M-value were calculated.
  
  
  RESULTS
  Patients receiving colestimide showed significant decreases in glucose levels 2 hours after breakfast (from 216.9 +/- 37.2 mg/dl before treatment to 191.1 +/- 40.9 mg/dl after treatment; p=0.008), in the J-index (from 42.6 +/- 14.5 to 32.6 +/- 9.8; p<0.001), and in the M-value (from 23.1 +/- 12.1 to 14.6 +/- 7.1; p<0.001).
  
  
  CONCLUSIONS
  In patients with type 2 diabetes and hyperlipidemia, colestimide was suggested to have blood glucose-lowering activity as does acarbose.
authors.affiliation: Department of Functional Pathophysiology for Human Organs, Nippon Medical School Graduate School of Medicine, Tokyo, Japan. t-suzuki@nms.ac.jp
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Suzuki
authors.forename: Kenzo
authors.initials: K
authors.lastname: Oba
authors.forename: Shoko
authors.initials: S
authors.lastname: Futami
authors.forename: Kazunari
authors.initials: K
authors.lastname: Suzuki
authors.forename: Motoshi
authors.initials: M
authors.lastname: Ouchi
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Igari
authors.forename: Noriaki
authors.initials: N
authors.lastname: Matsumura
authors.forename: Kentaro
authors.initials: K
authors.lastname: Watanabe
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kigawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nakano
mesh_terms: D020909:Acarbose / Q000627:therapeutic use*; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004811:Epichlorohydrin / Q000627:therapeutic use*; D005260:Female; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007093:Imidazoles / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D012117:Resins, Synthetic / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007093:Imidazoles; D008055:Lipids; D012117:Resins, Synthetic; C417427:colestimide; D004811:Epichlorohydrin; D020909:Acarbose